SCYNEXIS 3Q 2026: Revenue $0, EPS ($0.71) — 10-Q Summary
SCYNEXIS reported $0 revenue in 3Q 2026, down from $334K a year earlier, with a net loss of $8.46M. EPS was ($0.71), improved from ($1.38) YoY. R&D costs decreased due to a terminated study, offset by higher clinical spending. The company plans Phase 2 trials for SCY-770 and SCY-247, with BARDA providing up to $213.9M in funding.
How this was made
The 30-second read
Why it matters
The BARDA contract and Phase 1 results provide new catalysts for the stock, while zero revenue underscores ongoing cash challenges.
Market read
First‑report of Q3 results and trial data creates a short‑term trading opportunity for SCYX.
What to watch
Potential dilution from future financing needs and reliance on BARDA funding.
Background
SCYNEXIS filed its Q3 2026 10‑Q, highlighting zero license revenue, narrowed loss, and progress on two clinical programs.
Ticker impact
SCYNEXIS reported Q3 2026 revenue of $0, disclosed Phase 1 results for SCY-770 and SCY-247, and announced a BARDA contract up to $213.9M.
potential modest upside as investors price in trial progress and BARDA funding
Trial data and contract are material for a biotech, but lack of revenue tempers enthusiasm.
Market effects
Biotech sector may see slight uplift from BARDA funding news.
U.S. biotech investors could react positively.
Limited to biotech investors; no broad market effect.
Counterpoint
Revenue collapse suggests deeper cash burn risk; trial data may not translate to commercial success.
Key entities
- companySCYNEXIS
Biotech firm developing SCY‑770 and SCY‑247.
- government_agencyBARDA
U.S. Biomedical Advanced Research and Development Authority providing contract funding.